Opinion|Videos|September 9, 2024
Looking Beyond Type 2 Inflammation in Atopic Dermatitis
Focusing on the complex pathophysiology of atopic dermatitis, Lindsay S. Ackerman, MD, FAAD, discusses the importance of looking beyond type 2 inflammation while treating patients.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- With better understanding of the pathophysiology of atopic dermatitis, how important is to look beyond type 2 inflammation?
Advertisement
Related to this article
April Armstrong, MD, MPH, discusses 1-year RELIEVE-AD-PEDs data on rapid, sustained dupilumab disease control in adolescents with atopic dermatitis.
In a phase 3 study, telikibart achieved EASI-75 in 69.6% of adult patients with atopic dermatitis at Week 16, with rates above 94% by Week 52.
An indirect comparison finds higher placebo-adjusted skin and itch responses with upadacitinib vs nemolizumab in atopic dermatitis.
Tilrekimig, a trispecific IL-4/IL-13/TSLP antibody, met its EASI-75 primary endpoint at all doses in a phase 2 atopic dermatitis trial.
Advertisement
Advertisement
Trending on HCPLive
1
The Benefits and Limits of Enlicitide, With Ninel Hovnanians, MD
2
Ritlecitinib Stabilizes Vitiligo in Tranquillo Trial, With Iltefat Hamzavi, MD
3
5 Gastroenterology Headlines You Missed in September 2026
4
6 Nephrology Headlines You Missed in September 2026
5